Dobney Hypertension Centre, Medical School - Royal Perth Hospital Unit/Royal Perth Hospital Research Foundation, University of Western Australia, Perth, Western Australia.
Department of Medicine, Endocrine Hypertension Group, Hudson Institute of Medical Research.
J Hypertens. 2023 Apr 1;41(4):632-637. doi: 10.1097/HJH.0000000000003379. Epub 2023 Jan 30.
Raised blood pressure (BP) remains the single most important modifiable risk factor contributing to cardiovascular and all-cause mortality in Australia and worldwide. May Measurement Month , a global BP measurement and screening campaign initiated by the International Society of Hypertension and carried out in Australia since its inception in 2017, aimed at obtaining standardized BP measurements from members of the community to increase awareness of high BP and its associated risks.
Adults participants (≥18 years) were recruited through opportunistic sampling across Australia during the month of May in 2017, 2018 and 2019. Trained volunteers recorded BP readings in a standardized manner and collected data on demographic, lifestyle factors and comorbidities. Hypertension was defined as SBP of at least 140 mmHg, or DBP of at least 90 mmHg, or taking antihypertensive medication. Data were collated centrally and analysis was carried out using regression models to evaluate the associations between BP and participant characteristics.
A total of 10 046 participants were screened, of whom 3097 (31.0%) had hypertension, only 48.5% were aware of their condition and 44.4% were taking antihypertensive medication. Of those taking antihypertensive medication, 53.2% were controlled to less than 140/90 mmHg, whereas the remaining 46.8% of participants had BP of at least 140/90 mmHg suggestive of inadequately treated hypertension.
Consecutive data obtained over a 3-year period in Australia demonstrated stagnating awareness, treatment and control rates with the latter two being substantially lower than global rates and those in other high-income countries. Concerted efforts from all stakeholders will be required to help overcome the unacceptably poor rates of BP treatment and control in Australia.
升高的血压（BP）仍然是导致澳大利亚和全球心血管疾病和全因死亡率的最重要的可改变危险因素。自 2017 年国际高血压学会发起并在澳大利亚开展以来，“五月测量月”一直是一项全球性的血压测量和筛查活动，旨在从社区成员中获得标准化的血压测量值，以提高对高血压及其相关风险的认识。
在 2017 年、2018 年和 2019 年 5 月期间，通过在澳大利亚各地的机会性抽样招募成年参与者（≥18 岁）。经过培训的志愿者以标准化方式记录血压读数，并收集人口统计学、生活方式因素和合并症的数据。高血压定义为收缩压至少 140mmHg，或舒张压至少 90mmHg，或服用抗高血压药物。数据由中央机构汇总，使用回归模型进行分析，以评估血压与参与者特征之间的关系。
共筛查了 10046 名参与者，其中 3097 名（31.0%）患有高血压，只有 48.5%的人知道自己的病情，44.4%的人正在服用抗高血压药物。在服用抗高血压药物的患者中，53.2%的患者血压控制在 140/90mmHg 以下，而其余 46.8%的患者血压至少为 140/90mmHg，提示高血压治疗不足。
在澳大利亚连续 3 年获得的数据表明，高血压的知晓率、治疗率和控制率停滞不前，后两者明显低于全球水平和其他高收入国家的水平。需要所有利益攸关方共同努力，以帮助克服澳大利亚高血压治疗和控制率低得令人无法接受的问题。
